The Grünenthal Group: International, successful, innovative
Who we are...
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
We are an entrepreneurial specialist delivering true benefits to patients.
By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is one of five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 20 percent of revenues in 2015. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and currently approx. 5,300 employees are working for the Grünenthal Group worldwide.
In 2015, Grünenthal achieved revenues of € 1.2 bn.
... and what we do
- In-licensing or Acquisition of Projects defined in our Areas of Interest in various development stages (from research to launched products) and countries
- Out-Licensing/ Partnerships or Divestments in selected countries in different development stages
- Co-Promotion/Co-Marketing Agreements for approved products
- Alliance Management: A dedicated contact person for all partner relationships on strategic, contractual and other general matters between the two parties.